MERCK Kommanditgesellschaft auf Aktien

XETRA MRK.DE

MERCK Kommanditgesellschaft auf Aktien Cash and Short-Term Investments for the year ending December 31, 2023: USD 2.66 B

MERCK Kommanditgesellschaft auf Aktien Cash and Short-Term Investments is USD 2.66 B for the year ending December 31, 2023, a 51.60% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

MERCK Kommanditgesellschaft auf Aktien Cash and Short-Term Investments for the year ending December 31, 2022 was USD 1.76 B, a -4.91% change year over year.
MERCK Kommanditgesellschaft auf Aktien Cash and Short-Term Investments for the year ending December 31, 2021 was USD 1.85 B, a 32.79% change year over year.
MERCK Kommanditgesellschaft auf Aktien Cash and Short-Term Investments for the year ending December 31, 2020 was USD 1.39 B, a 117.51% change year over year.
MERCK Kommanditgesellschaft auf Aktien Cash and Short-Term Investments for the year ending December 31, 2019 was USD 639.67 M, a -74.35% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

XETRA: MRK.DE

MERCK Kommanditgesellschaft auf Aktien

CEO	Ms. Belen Garijo Lopez M.D.
IPO Date	June 26, 1998
Location	Germany
Headquarters	Frankfurter Strasse 250
Employees	62,176
Sector	Healthcare
Industries Biotechnology 3D Printing Chemicals & Advanced Materials Cosmetics Eyewear Hardware & Electronics Pharmaceuticals Plastics

Description

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.

Key trends

Past 5 years